The TENEO excimer laser by Bausch + Lomb is showing promising results in treating myopia and myopic astigmatism. Data from a 9-month FDA study presented at the American Academy of Ophthalmology reveals significant improvements in visual acuity and patient-reported outcomes following LASIK procedures performed with the TENEO laser.
Key Findings from the Study
The study, which included over 300 eyes with myopia and myopic astigmatism ranging from plano to -11.5 diopters of sphere and up to 3 diopters of myopic astigmatism, demonstrated that the TENEO laser met all standard safety and efficacy criteria for FDA approval. According to George O. Waring, IV, MD, from the Waring Vision Institute, the results are among the best seen with an excimer laser to date.
"More than a third of eyes gained a line of best corrected visual acuity after LASIK. That's really something special," said Dr. Waring. The study also found that patients were three times more likely to achieve 20/16 vision or better after LASIK compared to their preoperative vision with glasses or contact lenses.
Refractive Stability and Patient Satisfaction
Manifest refractive spherical equivalent (MRSE) was measured at -0.04 at 9 months, demonstrating excellent refractive stability over time. Patient-reported outcomes indicated significant improvements in nighttime glare, halos, and overall quality of vision after LASIK compared to before the procedure with glasses or contact lenses. Contrast sensitivity measurements were also better after LASIK with the TENEO laser.
Implications for Refractive Surgery
The TENEO laser represents a significant advancement in refractive surgery, offering improved outcomes and enhanced patient satisfaction. With its recent FDA approval and promising clinical data, the TENEO laser is poised to become a valuable tool for refractive surgeons in correcting myopia and myopic astigmatism.
